On September 8, 2021 SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, reported that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at two upcoming virtual investor conferences in Septembe (Press release, SAB Biotherapeutics, SEP 8, 2021, View Source [SID1234587426])r. Presentation details can be found below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Investment Conference.
Format: Pre-recorded presentation available for on-demand viewing
Date/Time: Monday, September 13 at 7:00 a.m. ET through Sunday, December 12 at 7:00 a.m. ET
Registration Link
Baird Global Healthcare Conference
Format: Fireside chat
Date/Time: Tuesday, September 14 at 12:50 p.m. ET
Registration Link
An on-demand webcast of the H.C. Wainwright presentation and archived replay of the Baird fireside chat will be accessible through the "News" section of the company’s website at www.sabbiotherapeutics.com

On June 22, 2021, SAB announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP). The transaction is expected to close in the fourth quarter of 2021.

On September 8, 2021 BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for traditionally undruggable targets, reported that Irene Yuan, Co-Founder and Executive Vice President of BridGene Biosciences, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 (Press release, Bridgene Biosciences, SEP 8, 2021, https://www.prnewswire.com/news-releases/bridgene-biosciences-to-present-at-the-virtual-hc-wainwright-23rd-annual-global-investment-conference-301370895.html [SID1234587444]). The prerecorded presentation will be available starting at 7 a.m. ET on September 13, 2021, and can be accessed via the conference’s virtual platform by registered conference attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Ms. Yuan will provide an overview of BridGene’s proprietary chemoproteomics platform technology, IMTAC (Isobaric Mass Tagged Affinity Characterization), and highlight recent corporate achievements. Currently, about 90% of disease-causing proteins cannot be targeted by traditional therapies due to the lack of a known addressable binding site. BridGene intends to change this by using its IMTAC platform. IMTAC enables the screening of small molecules against all the proteins in live cells to discover drug candidates for high value and hard-to-drug targets that cause disease. BridGene can perform IMTAC screening for both covalent and non-covalent molecules, setting the company apart from its peers. By combining IMTAC with phenotypic screening, BridGene can also discover previously unknown mechanisms for disease treatments by identifying new targets responsible for disease characteristics in cell models, a unique differentiator from its peers.

Ms. Yuan, Dr. Ping Cao (Co-Founder and Chief Executive Officer of BridGene), and other members of the BridGene management team will be participating in virtual one-on-one meetings.

On September 8, 2021 Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, reported preliminary, unaudited revenue for the month of August 2021 (Press release, Biofrontera, SEP 8, 2021, View Source [SID1234587391]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s preliminary, unaudited revenue from product sales in August 2021 amounted to approximately EUR 1,485 thousand, compared to EUR 1,341 thousand in August 2020, an increase of 11%.

Preliminary revenues from product sales in the US were around EUR 1,027 thousand compared to EUR 917 thousand in August 2020, an increase of 12%. In Germany, revenues from product sales amounted to approximately EUR 349 thousand, compared to EUR 345 thousand in August 2020, a slight increase of 1%. In the rest of Europe, the Company generated product sales of around EUR 109 thousand, compared to EUR 79 thousand in August 2020, a plus of 38%.

Due to the pandemic, the monthly and year-to-date sales development is compared with sales in 2019 for increased transparency. As such, an increase of 11% in August 2021 total product sales was achieved in all markets compared to August 2019. In the USA, product sales increased by about 4% compared to August 2019. In August 2021, product sales were up by around 36% in Germany and product sales in the remaining European markets increased by approximately 7% compared to August 2019.

Compared to 2019, product sales in all markets were down by around 2% compared to sales in the period January to August 2021. Year-to-date product sales in 2021 increased by around 25% in Germany and by 21% in the rest of the European market compared to the same period in 2019. Product revenue in the US market was down 12%, mainly due to the weak sales months of January and February this year due to the pandemic as well as the lack of or lower sales of Aktipak and Xepi compared to the period January to August 2019.

On September 8, 2021 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, reported that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 (Press release, Xenetic Biosciences, SEP 8, 2021, https://ir.xeneticbio.com/news/detail/115/xenetic-biosciences-inc-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference [SID1234587409]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be available for viewing on-demand beginning Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (xeneticbio.com). The webcast replay will be archived for 90 days following the event.

On September 8, 2021 CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, reported that Steven A. Kriegsman, the Company’s Chairman and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which is taking place virtually September 13-15, 2021 (Press release, CytRx, SEP 8, 2021, View Source [SID1234587427]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Kriegsman’s presentation will focus on CytRx’s high-potential pipeline and assets, including its licensing agreements with ImmunityBio, Inc. and Orphazyme A/S. The presentation will also discuss the Company’s assessment of its Centurion BioPharma subsidiary and its LADR Platform, which aims to concentrate ultra-high-potency drugs in solid tumors and minimize systemic toxicity. In addition to the LADR Platform, the technology includes the ACDx diagnostic, which was developed to allow oncologists to determine which patients can benefit from the ultra-high-potency drugs.

The virtual presentation will be available for on-demand access at this link and on CytRx’s website under the News & Events section beginning the week of September 13th.